Theravance Biopharma
TBPH
162 hedge funds and large institutions have $706M invested in Theravance Biopharma in 2025 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 47 increasing their positions, 41 reducing their positions, and 11 closing their positions.
255% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 11
38% more capital invested
Capital invested by funds: $512M → $706M (+$194M)
20% more funds holding
Funds holding: 135 → 162 (+27)
15% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 41
3.19% more ownership
Funds ownership: 92.87% → 96.06% (+3.2%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
63% less call options, than puts
Call options by funds: $978K | Put options by funds: $2.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$9.87M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$9.18M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$4.94M |
| 4 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$3.93M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$3.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$6.51M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6.26M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5.49M |
| 4 |
JFG
Jefferies Financial Group
New York
|
-$3.05M |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$1.84M |
TBPH Hedge Fund Activity: Q3 2025 in Review
162 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2025, worth a combined $706M — up 38% from $512M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new TBPH positions and 11 closed out — a net gain of 28 holders — while 47 added to existing stakes and 41 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $9.87M. The largest seller was Park West Asset Management, cutting an estimated $6.51M.
- 162 institutional investors held Theravance Biopharma (TBPH) as of Q3 2025, up from 135 in Q2 2025.
- Funds reported $706M of Theravance Biopharma stock for Q3 2025, up 38% quarter-over-quarter.
- 39 funds opened new Theravance Biopharma positions in Q3 2025 and 11 closed out, a net change of +28 holders.
- The largest Theravance Biopharma buyer in Q3 2025 was Acadian Asset Management, an estimated $9.87M added.
- The largest Theravance Biopharma seller in Q3 2025 was Park West Asset Management, an estimated $6.51M sold.
Based on aggregated 13F filings for Q3 2025.